These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7244281)

  • 1. [Modification of schizophrenia by intensive neuroleptic therapy and the course of the disease after withdrawal of neuroleptic drugs].
    Steiner S
    Psychiatr Clin (Basel); 1980; 13(3-4):165-78. PubMed ID: 7244281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
    Wistedt B; Palmstierna T
    J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G; Coyle J; Tune L
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal].
    Ben Hadj Ali B; Dogui M; Ben Ammou S; Lôo H
    Encephale; 1995; 21(3):209-15. PubMed ID: 7649071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA; Silver MA
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA; Aderounmu AF
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroleptic withdrawal with remitted schizophrenics: a naturalistic follow-up study.
    Nishikawa T; Hayashi T; Koga I; Uchida Y
    Psychiatry; 2007; 70(1):68-79. PubMed ID: 17492913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of fluphenazine in plasma after decanoate withdrawal.
    Gitlin MJ; Midha KK; Fogelson D; Nuechterlein K
    J Clin Psychopharmacol; 1988 Feb; 8(1):53-6. PubMed ID: 3351000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic-induced supersensitivity psychosis: retrospective study of schizophrenic inpatients.
    Hunt JI; Singh H; Simpson GM
    J Clin Psychiatry; 1988 Jul; 49(7):258-61. PubMed ID: 2899071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Social integration of long-term paraphrenic patients with low-dose depot neuroleptic medication].
    Lesch OM; Dietzel-Rogan M; Musalek M; Rajna P; Rustembegovich A; Schjerve M; Walter H
    Psychiatr Prax; 1985 Mar; 12(2):63-8. PubMed ID: 3887443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early hospital experience with fluphenazine decanoate.
    Small JG; Kellams J
    Dis Nerv Syst; 1974 Oct; 35(10):453-6. PubMed ID: 17894058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
    Boza RA; Milanes F; Starkey T; Slater V; Dominguez F
    J Clin Psychiatry; 1988 Jun; 49(6):245. PubMed ID: 2897960
    [No Abstract]   [Full Text] [Related]  

  • 14. Continuation electroconvulsive therapy for relapse prevention in middle-aged and elderly patients with intractable catatonic schizophrenia.
    Suzuki K; Awata S; Takano T; Ebina Y; Iwasaki H; Matsuoka H
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):481-9. PubMed ID: 16048455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Maintenance electroconvulsive therapy and treatment of refractory schizophrenia].
    Lévy-Rueff M; Jurgens A; Lôo H; Olié JP; Amado I
    Encephale; 2008 Oct; 34(5):526-33. PubMed ID: 19068343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of long-term treatment with depot neuroleptics in schizophrenic patients].
    Klein A; Ehle G
    Psychiatr Neurol Med Psychol (Leipz); 1988 Mar; 40(3):159-67. PubMed ID: 3132729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A study on relapse of schizophrenic patients--10-year-follow-up investigation after initial admission].
    Uchida S
    Seishin Shinkeigaku Zasshi; 1996; 98(5):299-319. PubMed ID: 8741284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient.
    Aruna AS; Murungi JH
    Ann Pharmacother; 2005 Jun; 39(6):1131-5. PubMed ID: 15840734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.
    Viguera AC; Baldessarini RJ; Hegarty JD; van Kammen DP; Tohen M
    Arch Gen Psychiatry; 1997 Jan; 54(1):49-55. PubMed ID: 9006400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilization and depot neuroleptic dosages.
    Weiden P; Schooler NR; Severe JB; Lee JH; Schulz SC
    Psychopharmacol Bull; 1993; 29(2):269-75. PubMed ID: 8290676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.